HEPATIC STEATOSIS AS DIABETES TYPE 2 PREDICTOR

被引:9
|
作者
Loureiro, Carolina [1 ]
Martinez-Aguayo, Alejandro [1 ]
Campino, Carmen [2 ]
Carvajal, Cristian [2 ]
Fardella, Carlos [2 ]
Garcia, Hernan [1 ]
机构
[1] Pontificia Univ Catolica Chile, Div Pediat, Unidad Endocrinol Pediat, Santiago 8330074, Chile
[2] Pontificia Univ Catolica Chile, Dept Endocrinol, Santiago 8330074, Chile
关键词
Non alcoholic fatty liver disease (NAFLD); Steatohepatitis; Alanine aminotransferase; Insulin resistance; Type; 2; diabetes; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; ALANINE AMINOTRANSFERASE; OBESE ADOLESCENTS; ADIPOSE-TISSUE; CHILDREN; ADIPONECTIN; PREVALENCE; INTERLEUKIN-6; OVERWEIGHT;
D O I
10.3305/nh.2014.29.2.7098
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance (IR) and increased type 2 diabetes (T2D). Alanine aminotransferase (ALT) is recognized as biochemical marker of NAFLD, currently used as screening for this disease. Objective: To estimate the associations between (ALT) with anthropometric variables, insulin resistance and inflamatory markers in pediatric population. Patients and Method: we studied 348 subjects (52.7% females), aged between 4.9 and 15.6 years. Blood samples for measuring: AST, ALT, glycaemia, insulin, lipid profile, hsCRP TNF-alpha, IL-6 and adiponectin. We calculate HOMA-IR, QUICKI y el HOMA-beta. The results are expressed are expressed as median interquartile range. Variables were log10 transformed before Pearson correlations analyze. Results: Serum ALT levels were positively associated with BMI-SDS (r = 0.335), waist/height ratio (r = 0.358), insulin (r = 0.33), HOMA-IR (r = 0.33), HOMA-beta (r = 0.26), TG/HDL-c (r = 0.2), hsCRP (r = 0.3); and a negative association with QUICKI (r = -0.25) and adiponectin (r = -0.113). Non-association with ALT, glycaemia, TNF-a and IL-6 was found. Conclusion: Our study demonstrated that ALT, but not AST, was significantly correlated with of insulin resistance and inflamatory markers, all of them recognized as risk parameters of pre diabetes stage. ALT should be part of the evaluation of all obesity children, mainly those with other cardiometabolic risk factors, since it could predict later development of T2DM. Further imaging studies are necessary to confirm fatty liver disease in this population.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 50 条
  • [1] High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus
    Gupta, Aanchal
    Anoop, Shajith
    Ansari, Irshad Ahmad
    Prakash, Satya
    Misra, Anoop
    CLINICAL NUTRITION ESPEN, 2021, 46 : 519 - 526
  • [2] Hepatic Steatosis and Low Cardiorespiratory Fitness in Youth With Type 2 Diabetes
    Wittmeier, Kristy D. M.
    Wicklow, Brandy A.
    MacIntosh, Andrea C.
    Sellers, Elizabeth A. C.
    Ryner, Lawrence N.
    Serrai, Hacene
    Gardiner, Philip F.
    Dean, Heather J.
    McGavock, Jonathan M.
    OBESITY, 2012, 20 (05) : 1034 - 1040
  • [3] Steatosis and NASH in type 2 diabetes
    Hu, Mengyue
    Phan, Franck
    Bourron, Olivier
    Ferre, Pascal
    Foufelle, Fabienne
    BIOCHIMIE, 2017, 143 : 37 - 41
  • [4] Hepatic steatosis and type 2 diabetes mellitus.
    Clark J.M.
    Diehl A.M.
    Current Diabetes Reports, 2002, 2 (3) : 210 - 215
  • [5] The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes
    Hashimoto, Yoshitaka
    Osaka, Takafumi
    Fukuda, Takuya
    Tanaka, Muhei
    Yamazaki, Masahiro
    Fukui, Michiaki
    ENDOCRINE JOURNAL, 2016, 63 (10) : 877 - 884
  • [6] Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes
    Fennoun, Halima
    El Mansouri, Souhaila
    Tahiri, Mohammed
    Haraj, Nassim Essabah
    El Aziz, Siham
    Hadad, Fouad
    Hliwa, Wafaa
    Badr, Wafaa
    Chadli, Asma
    PAN AFRICAN MEDICAL JOURNAL, 2020, 37 : 270
  • [7] Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening
    Poustchi, Hossein
    Alaei-Shahmiri, Fariba
    Aghili, Rokhsareh
    Nobarani, Sohrab
    Malek, Mojtaba
    Khamseh, Mohammad E.
    ARCHIVES OF IRANIAN MEDICINE, 2021, 24 (03) : 177 - 186
  • [8] Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations
    Apostolov, Ross
    Gianatti, Emily
    Wong, Darren
    Kutaiba, Numan
    Gow, Paul
    Grossmann, Mathis
    Sinclair, Marie
    WORLD JOURNAL OF HEPATOLOGY, 2022, 14 (04) : 754 - U128
  • [9] Hepatic Steatosis Index Is Associated with Type I Diabetes Complications
    Tripolino, Cesare
    Irace, Concetta
    Cutruzzola, Antonio
    Parise, Martina
    Barone, Milena
    Scicchitano, Caterina
    Cortese, Claudio
    Gnasso, Agostino
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2405 - 2410
  • [10] The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis
    Carvalho, Jose A. M.
    Barengo, Noel C.
    Tuomilehto, Jaakko
    Conceicao, Raquel D.
    Santos, Raul D.
    ANNALS OF MEDICINE, 2011, 43 (06) : 487 - 494